dc.creatorMoreira D.D.O.
dc.creatorPereira J.A.
dc.creatorTaniguti A.P.T.
dc.creatorMatsumura C.Y.
dc.creatorRamos L.A.F.
dc.creatorAreas M.A.
dc.creatorNeto H.S.
dc.creatorMarques M.J.
dc.date2013
dc.date2015-06-25T19:12:18Z
dc.date2015-11-26T15:09:37Z
dc.date2015-06-25T19:12:18Z
dc.date2015-11-26T15:09:37Z
dc.date.accessioned2018-03-28T22:19:48Z
dc.date.available2018-03-28T22:19:48Z
dc.identifier
dc.identifierMuscle And Nerve. , v. , n. , p. - , 2013.
dc.identifier0148639X
dc.identifier10.1002/mus.23858
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84883733538&partnerID=40&md5=519bd0023fe63919c2d1692af292ce95
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/88741
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/88741
dc.identifier2-s2.0-84883733538
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1257857
dc.descriptionIntroduction: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. Methods: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Results: Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. Conclusions: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. © 2013 Wiley Periodicals, Inc.
dc.description
dc.description
dc.description
dc.description
dc.languageen
dc.publisher
dc.relationMuscle and Nerve
dc.rightsfechado
dc.sourceScopus
dc.titleSuramin Attenuates Dystrophin-deficient Cardiomyopathy In The Mdx Mouse Model Of Duchenne Muscular Dystrophy
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución